On July 25, three WeChat Official Accounts of Jiangsu Broadcasting Corporation, namely Jiangsu News, Jiangsu Traffic and Jiangsu Finance, simultaneously published an article titled “Starting Next Month, This Made-in-China Life-saving Drug for Leukemia Patients Becomes Reimbursable across the Country. Cheaper and Safer than Buying Them from India!”

Click this link to access the article on Jiangsu Finance: https://mp.weixin.qq.com/s/NDjZS4zXTlyV2p4qWMRyJA‍‍

Below is the Original Article:

Imatinib mesylate is an oral tyrosine kinase inhibitor and a first-line treatment for chronic myeloid leukemia (CML), increasing the 10-year survival to 85%~90%. The monthly treatment with imported drugs will cost over RMB20, 000, unaffordable for a considerable number of patients. A few patients go to great lengths to illegally purchase from India drugs with unguaranteed quality or even counterfeits, or fall victim to scams.

Hansoh initiated the imatinib localization project in 2009 and succeeded in 2013. Based on the merit of innovation, it obtained the grant from the “Significant New Drug Development” of the “12th Five-Year Plan”. Hansoh also invented a unique patented synthetic route which effectively improves quality and lowers costs.

With Hansoh’s Xinwei (Imatinib mesylate) being commercially available, the annual comprehensive treatment cost for patients with leukemia dropped by two-thirds. So far, Hansoh’s imatinib has benefited tens of thousands of patients. It has been reimbursable in Jiangsu since January 1 2015, later included into the 2017 National Reimbursement Drug List (NRDL) which is expected to be enforced nationwide starting from August this year.

Founded in July 1995, Hansoh has grown into a modern and innovative pharmaceutical group that engages in chemical and biological drugs development, pharmaceutical intermediates and API synthesis, preparation manufacturing and marketing. It’s recognized as a Key National High-tech Enterprise, one of China’s Top 20 pharmaceutical companies, and one of the major R&D and production bases for oncology and CNS drugs in China.

Hansoh attaches great importance to new drug development. It has purchased internationally advanced manufacturing and testing equipment, implemented a lean manufacturing process, and established a strict quality control system and internationally-aligned quality standards. Some APIs and preparations are certified by US FDA and exported to over 10 countries and regions in Europe, America, Asia and Africa.

Thanks to its premium-quality products and professional marketing, Hansoh sees continuous growth in its brand value and market share. Currently, the Company offers over 20 varieties covering six areas including CNS,oncology, anti-infectives,diabetes, gastrointestinal and cardiovascular. Oncology drugs Zefei, Pulaile, Gainuo, Xinwei and Xinmei, CNS drug Ameining, diabetes drug Fulaidi, and gastrointestinal drug Ruibote are all market leaders in terms of market share.

Hansoh also values talents, demonstrated by the multiple promotion pathways for its employees. Just the 3-year free lodging benefit for new recruits must be attractive enough to incur jealousy of other companies’ employees.